Lexaria Bioscience Corp (LEXX) Stock Price, Quote & News

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology

Sector: Healthcare

Phone: 250 765 6424

Website: lexariabioscience.com

Address:

740 McCurdy Road, Suite 100, Kelowna, Canada

Makingmillions192 Aug. 19 at 10:56 AM

$LEXX I’m not sure why anyone would be trading this. Your holding for trial #7 data, an MTA conversion, and more business development announcements. Longs have been waiting years for this right now 🔥

1 · Reply

jjvvv Aug. 19 at 8:49 AM

$LEXX should i set stop loss, trailing stop loss or nothing? And if yes at what amount?

1 · Reply

Yakko_Warner Aug. 19 at 2:28 AM

$LEXX some smartea pants .. what are we at pre rwv split now ?

1 · Reply

hovian Aug. 19 at 1:40 AM

$LEXX not long ago they declared 6MM cash... so I think the next way to collect will b hit the warrants that will vest at 16 or 17? maybe this time they not gonna print more shares... lets hope... I m praying management not to issue...

1 · Reply

Makingmillions192 Aug. 18 at 8:21 PM

$LEXX Great close lads 👏 Something big is brewing 👀 🍯 📈

0 · Reply

Makingmillions192 Aug. 18 at 7:30 PM

$LEXX Nice consolidation going into the bell - CHURN AND BURN baby 🔥

0 · Reply

Makingmillions192 Aug. 18 at 6:45 PM

$LEXX $12.12 make a wish 😘

0 · Reply

Makingmillions192 Aug. 18 at 6:36 PM

$LEXX Good is an understatement 💰

0 · Reply

AshleySchaeffer_BMW Aug. 18 at 6:27 PM

$LEXX feeling good to sit on a big bag here, $50 before long imo at a minimum on big mta announcement!

0 · Reply

aaaaas Aug. 18 at 6:26 PM

$LEXX oh I mean it's not even at April peak yet, still fuck this stock. Let me get back in at 4.9

2 · Reply

Lexaria Bioscience enters MTA with PegBio

Aug 13, 2026, 9:00 AM EDT - 5 days ago

Lexaria Enters a Material Transfer Agreement With PegBio

Aug 13, 2026, 9:00 AM EDT - 5 days ago

Lexaria Enters a Material Transfer Agreement with PegBio

2026-08-03T14:05:24.000Z - 15 days ago

Lexaria Bioscience Corp trading resumes

2026-08-03T14:00:38.000Z - 15 days ago

Lexaria Bioscience Corp trading halted, volatility trading pause

2026-07-31T23:55:25.000Z - 18 days ago

Lexaria Bioscience Corp trading halted, news pending

2026-07-30T15:10:56.000Z - 19 days ago

Lexaria Bioscience announces effective date for reverse stock split

Jul 30, 2026, 11:00 AM EDT - 19 days ago

Lexaria Announces Effective Date for Reverse Stock Split

Jul 13, 2026, 7:00 AM EDT - 5 weeks ago

Lexaria Bioscience Quarterly report: Q3 2026

Jul 6, 2026, 9:10 AM EDT - 6 weeks ago

Lexaria Updates Business Development

2026-06-25T13:15:18.000Z - 7 weeks ago

Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing

NVO

Jun 25, 2026, 9:10 AM EDT - 7 weeks ago

Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule

Jun 25, 2026, 9:10 AM EDT - 7 weeks ago

Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule

2026-06-23T15:26:36.000Z - 2 months ago

Lexaria Bioscience begins dosing in animal study GLP-1-A26-1

Jun 23, 2026, 9:25 AM EDT - 2 months ago

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Jun 23, 2026, 9:25 AM EDT - 2 months ago

Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule

2026-06-17T13:42:22.000Z - 2 months ago

Lexaria Bioscience provides update on GLP-1 oral pill market

Jun 17, 2026, 9:25 AM EDT - 2 months ago

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

Jun 17, 2026, 9:25 AM EDT - 2 months ago

GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

2026-06-09T13:34:05.000Z - 2 months ago

Lexaria announces dosing completion in 2026 Animal Study 2

Jun 9, 2026, 9:25 AM EDT - 2 months ago

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.

Jun 9, 2026, 9:25 AM EDT - 2 months ago

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Jun 3, 2026, 9:25 AM EDT - 2 months ago

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Jun 3, 2026, 9:25 AM EDT - 2 months ago

Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program

May 27, 2026, 7:00 AM EDT - 3 months ago

Lexaria Bioscience Slides: Corporate presentation

2026-05-19T13:27:07.000Z - 3 months ago

Lexaria Bioscience announces ethics approval for Human Pilot Study 7

NVO

May 19, 2026, 9:15 AM EDT - 3 months ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

May 7, 2026, 9:25 AM EDT - 3 months ago

Lexaria Bioscience Releases Second Episode of Investor Video Series

2026-05-05T13:24:25.000Z - 3 months ago

Lexaria Bioscience provides update on Human Pilot Study #7

NVO

May 5, 2026, 9:10 AM EDT - 3 months ago

Lexaria Updates Progress on Human Study #7

May 1, 2026, 9:25 AM EDT - 3 months ago

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

2026-04-29T13:16:24.000Z - 3 months ago

Lexaria Bioscience extends material transfer agreement with pharma company

Apr 29, 2026, 9:10 AM EDT - 3 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

2026-04-23T13:23:01.000Z - 4 months ago

Lexaria Bioscience launches new study to examine next-gen GLP-1 drugs

Apr 23, 2026, 9:05 AM EDT - 4 months ago

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

2026-04-21T15:02:42.000Z - 4 months ago

Lexaria Bioscience provides update on GLP-1 oral pill market

Apr 21, 2026, 9:10 AM EDT - 4 months ago

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

2026-04-15T13:24:10.000Z - 4 months ago

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

Apr 15, 2026, 9:10 AM EDT - 4 months ago

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Lexaria Bioscience Quarterly report: Q2 2026

2026-04-07T13:40:33.000Z - 4 months ago

Lexaria Bioscience ‘applauds’ Eli Lilly’s Foundayo drug approval

LLY

Apr 7, 2026, 9:10 AM EDT - 4 months ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

2026-04-01T13:26:48.000Z - 4 months ago

Lexaria Bioscience to begin new human clinical study in GLP-1

Apr 1, 2026, 9:20 AM EDT - 4 months ago

Lexaria to Begin New Human Clinical Study in GLP-1

2026-03-26T13:25:26.000Z - 5 months ago

Lexaria receives five new patents, including two for diabetes treatment

Mar 26, 2026, 9:20 AM EDT - 5 months ago

Lexaria's Robust Patent Portfolio Continues to Grow

Mar 24, 2026, 9:15 AM EDT - 5 months ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Mar 4, 2026, 9:25 AM EST - 5 months ago

Lexaria Announces New R&D Plans for 2026

Feb 5, 2026, 9:15 AM EST - 6 months ago

Lexaria Announces Positive Final Results From Human Pilot Study #5

Jan 22, 2026, 9:20 AM EST - 7 months ago

Lexaria Awarded Six Additional Patents

Jan 13, 2026, 7:00 AM EST - 7 months ago

Lexaria Bioscience Quarterly report: Q1 2026

Jan 12, 2026, 9:10 AM EST - 7 months ago

Lexaria Releases Annual Letter from the CEO

Dec 30, 2025, 9:20 AM EST - 8 months ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 29, 2025, 7:00 AM EST - 8 months ago

Lexaria Bioscience Registration statement: Registration filing

Dec 23, 2025, 9:29 AM EST - 8 months ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 16, 2025, 4:00 PM EST - 8 months ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 8 months ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 10, 2025, 7:00 AM EST - 8 months ago

Lexaria Bioscience Proxy statement: Proxy filing

Dec 5, 2025, 7:00 AM EST - 9 months ago

Lexaria Bioscience Registration statement: Registration filing

Nov 28, 2025, 7:00 AM EST - 9 months ago

Lexaria Bioscience Annual report: Q4 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Lexaria Bioscience Registration statement: Registration filing

Oct 9, 2025, 9:20 AM EDT - 11 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Sep 29, 2025, 4:30 PM EDT - 11 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 11 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 19, 2025, 11:20 AM EDT - 11 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Aug 14, 2025, 9:20 AM EDT - 1 year ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 6, 2025, 9:20 AM EDT - 1 year ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Jul 28, 2025, 9:25 AM EDT - 1 year ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 23, 2025, 9:25 AM EDT - 1 year ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Lexaria Bioscience Quarterly report: Q3 2025

May 12, 2025, 9:00 AM EDT - 1 year ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Apr 28, 2025, 4:15 PM EDT - 1 year ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Makingmillions192 Aug. 19 at 10:56 AM

1 · Reply

jjvvv Aug. 19 at 8:49 AM

$LEXX should i set stop loss, trailing stop loss or nothing? And if yes at what amount?

1 · Reply

Yakko_Warner Aug. 19 at 2:28 AM

$LEXX some smartea pants .. what are we at pre rwv split now ?

1 · Reply

hovian Aug. 19 at 1:40 AM

1 · Reply

Makingmillions192 Aug. 18 at 8:21 PM

$LEXX Great close lads 👏 Something big is brewing 👀 🍯 📈

0 · Reply

Makingmillions192 Aug. 18 at 7:30 PM

$LEXX Nice consolidation going into the bell - CHURN AND BURN baby 🔥

0 · Reply

Makingmillions192 Aug. 18 at 6:45 PM

$LEXX $12.12 make a wish 😘

0 · Reply

Makingmillions192 Aug. 18 at 6:36 PM

$LEXX Good is an understatement 💰

0 · Reply

AshleySchaeffer_BMW Aug. 18 at 6:27 PM

$LEXX feeling good to sit on a big bag here, $50 before long imo at a minimum on big mta announcement!

0 · Reply

aaaaas Aug. 18 at 6:26 PM

$LEXX oh I mean it's not even at April peak yet, still fuck this stock. Let me get back in at 4.9

2 · Reply

Makingmillions192 Aug. 18 at 6:18 PM

$LEXX It’s going a lot higher than that based on what I’m seeing. I think it could finish the day close to $14. Bid stacking, and it looks like it’s really close to hyperbolic momentum here.

0 · Reply

hovian Aug. 18 at 6:13 PM

$LEXX who wanna participate in a final day run? +$12 in the cards?

0 · Reply

Fenderstrat68 Aug. 18 at 6:05 PM

$LEXX now, that s the first RVS that actually seems to be having beneficial results for investors!! Let's keep it going!

0 · Reply

Makingmillions192 Aug. 18 at 5:28 PM

$LEXX One of the best things with the PegBio MTA is that the market understood that what the CEO has been telling us recently was 100% accurate. The business development room is buzzing. Outside of the existing MTA partner and upcoming data drops there could be other irons in the fire. And I think this repricing is accounting for that as well. Super exciting times here.

0 · Reply

Makingmillions192 Aug. 18 at 4:55 PM

$LEXX Rani ran to a 250m mkt cap on their deal at the end of 2025. Not out of the question to say we can 10x from here if the existing MTA partner structures something similar. Very exciting 💰 $RANI $LLY $VKTX $NVO

0 · Reply

Makingmillions192 Aug. 18 at 4:41 PM

$LEXX Ask clear to $12, bidders buying a half increment cents to avoid detection. This is a heavy accumulation move so far IMO..

0 · Reply

prismmarketview Aug. 18 at 4:14 PM

PRISM Mid-Day Movers: Pharmaceuticals and MedTech are Today’s Leaders. Amylyx Pharmaceuticals (NASDAQ: $AMLX ) is rallying sharply today, up 49.42% to 32.02 from Monday’s 21.43 close after opening at 29.93. bioAffinity Technologies (NASDAQ: $BIAF ) is up 19.92% today to 0.4701 from Monday’s 0.392 close, but the session has been highly volatile. Other Notable Movers: Duos Technologies Group, Inc. ($DUOT )up 12% Lexaria Bioscience Corp. ( $LEXX ) up 10% Mobix Labs, Inc. ($MOBX )down -15% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-medtech-are-todays-leaders-2/

0 · Reply

Makingmillions192 Aug. 18 at 4:04 PM

$LEXX Ask is so light now that big news will move this in a hurry

0 · Reply

AshleySchaeffer_BMW Aug. 18 at 3:58 PM

$LEXX looking good today, low vol steady climb up!

0 · Reply

KUMO2026 Aug. 18 at 3:39 PM

$LEXX very nice follow through

0 · Reply

hovian Aug. 18 at 3:38 PM

$LEXX once we cross 12 and 13 there will be no return ... just up

0 · Reply

hovian Aug. 18 at 3:35 PM

$LEXX oh my boy... just wait for NR study #7 outcomes ...

0 · Reply

Market Cap	17.05M
Revenue (ttm)	710,000.00
Net Income (ttm)	-11.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,676.06%
Debt to Equity Ratio	0.00

Volume	32,200
Avg Vol	14,116
Day's Range	N/A - N/A
Shares Out	1.65M
Stochastic %K	91%
Beta	0.38
Analysts	Strong Sell
Price Target	$3.50